Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $99.34, but acceptable to hold if already in. Reasons: Concentration risk — Counterparty: one specialty pharmacy; Leverage penalty (D/E 1.3): -0.5.
Mirum Pharmaceuticals markets three FDA-approved rare disease medicines: LIVMARLI for cholestatic pruritus in ALGS and PFIC, CTEXLI for CTX (approved Feb 2025), and CHOLBAM for bile acid synthesis disorders. Commercial revenue comes from direct US sales; pipeline includes... Read more
Hold if already holding. Not a fresh buy at $99.34, but acceptable to hold if already in. Reasons: Concentration risk — Counterparty: one specialty pharmacy; Leverage penalty (D/E 1.3): -0.5. Chart setup: Golden cross, above all MAs, RSI 51, MACD bullish. Maintain position. Not compelling to add more. Score 6.2/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.70, earnings proximity 52d clear, semi cycle peak clear, materials cycle peak clear). Suitability: moderate.
Recent developments
updated 2026-06-14Recent Developments — Mirum Pharmaceuticals, Inc.
Latest news
- NEWS MIRM Mirum Pharmaceuticals reports steep Q4 2025 EPS miss, while shares post a small gain in today's trading. - Crowd En — Newser negative
- NEWS Mirum Pharmaceuticals, Inc. (MIRM) expected to beat earnings estimates: What to know ahead of Q1 release - MSN — MSN positive
- NEWS Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $130.00 at Stifel Nicolaus - MarketBeat — MarketBeat positive
- NEWS Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance — Yahoo Finance Singapore positive
- NEWS Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo! Financ — Yahoo! Finance Canada positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHcounterpartyone specialty pharmacy10-K Item 1: 'We are commercializing Ctexli and Cholbam in the United States through one specialty pharmacy.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·2 ceiling hits
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $99.34, but acceptable to hold if already in. Reasons: Concentration risk — Counterparty: one specialty pharmacy; Leverage penalty (D/E 1.3): -0.5. Chart setup: Golden cross, above all MAs, RSI 51, MACD bullish. Maintain position. Not compelling to add more. Target $126.09 (+26.9%), stop $92.39 (−7.5%), A.R:R 3.0:1. Score 6.2/10, moderate confidence.
Take-profit target: $126.09 (+26.9% upside). Target $126.09 (+26.9%), stop $92.39 (−7.5%), A.R:R 3.0:1. Stop-loss: $92.39.
Concentration risk — Counterparty: one specialty pharmacy; Leverage penalty (D/E 1.3): -0.5; Consecutive earnings misses (2).
Mirum Pharmaceuticals, Inc. trades at a P/E of N/A (forward -178.0). TrendMatrix value score: 6.6/10. Verdict: Hold.
19 analysts cover MIRM with a consensus score of 4.3/5. Average price target: $145.
What does Mirum Pharmaceuticals, Inc. do?Mirum Pharmaceuticals markets three FDA-approved rare disease medicines: LIVMARLI for cholestatic pruritus in ALGS and...
Mirum Pharmaceuticals markets three FDA-approved rare disease medicines: LIVMARLI for cholestatic pruritus in ALGS and PFIC, CTEXLI for CTX (approved Feb 2025), and CHOLBAM for bile acid synthesis disorders. Commercial revenue comes from direct US sales; pipeline includes volixibat (PSC/PBC Phase 2b) and brelovitug (HDV Phase 3, acquired via Bluejay in Jan 2026).